- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01357525
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Radiation simulation will be done in Shadyside Radiation Oncology department Contrast-enhanced CT based simulation will be obtained prior to any adjuvant treatment (2-4 weeks post-op depending on healing). The target volume will be identified based on fiducial marker placement at time of surgery as well as a detailed discussion and image review with the operating surgeon. This are will be contoured on axial CT images obtained at 1.25 mm slice thickness. These volumes will then be reconstructed into a 3-dimensional image set for SBRT planning. Subjects will be simulated in the treatment position (supine with arms raised) on the CT scanner table the appropriate immobilization. Optiray® contrast will be administered intravenously at a flow rate of 2.5 mL/s. A helical CT scan of the abdomen will be acquired with intravenous contrast starting 30 seconds prior to CT acquisition.
A 4D CT data acquisition for the same axial extent will be obtained. The images will then be electronically transferred from the CT workstation via DICOM3 to the appropriate treatment planning workstation in the department of radiation oncology. Based on axial CT images, fiducial marker placement, review of the pathology report, and a detailed discussion with the operating surgeon, contours will be drawn of the clinical target volume (CTV), which is defined as the area at risk for microscopic disease. The planning target volume (PTV) will be equivalent to the CTV unless motion is detected on the 4D motion study. If there is motion, the amount of motion in the superior-inferior, lateral, and anterior-posterior directions will be the margin given. Surrounding normal and critical structures will also be contoured by the treating radiation oncologist including the kidneys, liver, small bowel, spinal cord, and stomach if necessary.
Stereotactic Body Radiotherapy Planning An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV.
Careful evaluation of each plan will be conducted by the radiosurgical team to ensure that normal tissues and critical structures tolerances are maintained.
The maximum dose (in Gy) within the treatment volume (MD), prescriptions dose (PD), and the ratio of MD/PD (as a measure of heterogeneity within the target volume), prescription isodose volume (PIV in mm3), tumor volume (TV in mm3), and the ratio of PIV/TV (as a measure of dose conformity of the treatment relative to the target) will be recorded.
Evaluation during treatment The subjects will be carefully followed while on active treatment and post-treatment for 24 months, or until death.
Treatment following SBRT All patients will have been seen in a multi-disciplinary pancreatic cancer clinic. As such, they will be set up with a medical oncologist. Following completion of SBRT as described in this protocol, the patient's medical oncologist may, at his/her discretion, administer systemic therapy according to the current standard of care or the UPMC pathways.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically proven adenocarcinoma of the pancreas that has been resected with a close (<2.5mm) or positive margin based on surgical and pathological findings.
- Subjects will be staged according to the 2010 AJCC staging system (Appendix E) with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tail
- PTV must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist
- Karnofsky performance status > 70 (ECOG 0-1)
- Age > 18
- Estimated life expectancy > 12 weeks
- Patient must have adequate renal function as defined by serum creatinine<1.5mg/dl obtained within 28 days prior to registration
- Patient must have adequate hepatic function as defined by total bilirubin <1.5 xIULN(institutional upper limit of normal) and either SGOT or SGPT <2.5xIULN, obtained within 28 days prior to registration.
- Patient must be able to swallow enteral medications. Patient must not require a feeding tube. Patient must not have intractable nausea or vomiting, GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, or uncontrolled inflammatory bowel disease (Chron's, ulcerative colitis).
- Ability to provide written informed consent
- Patient must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, history of myocardial infarction or cerebrovascular accident within 3 months prior to registration, uncontrolled diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patient must not be pregnant because of the risk of harm to the fetus. Nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from the treatment regimen. Women/men of reproductive potential must agree to use an effective contraception method.
Exclusion Criteria:
- Non-adenocarcinomas, adenosquamous carcinomas, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas are not eligible.
- Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
- Subjects with recurrent disease
- Prior radiation therapy to the upper abdomen or liver
- Prior chemotherapy
- Subjects in their reproductive age group should use an effective method of birth control. Subjects who are breast-feeding, or have a positive pregnancy test will be excluded from the study
- Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
- Concurrent serious infection
- Previous or current malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in situ, adequately treated basal cell or squamous cell carcinoma of the skin, and treated low-risk prostate cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Stereotactic Body Radiotherapy
|
An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV: 12 Gy x 3 fractions (36 Gy total)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local Progression-free Survival (LPFS) at 1-year
Time Frame: Up to 12 months
|
Percentage of patients that did not experience progressive disease (PD) in the target lesion.
Death or development of distant disease was not regarded as an event.
For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 12 months
|
Local Progression-free Survival (LPFS) at 2-years
Time Frame: Up to 24 months
|
Percentage of patients that did not experience progressive disease (PD) in the target lesion.
Death or development of distant disease was not regarded as an event.
For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Local Progression-free Survival (LPFS)
Time Frame: Up to 24 months
|
Percentage of patients without disease progression in target lesion from time from enrollment until one month.
Death or development of distant disease is not regarded as an event.
For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Regional Progression-free Survival (RPFS)
Time Frame: Up to 24 months
|
Time duration that patients that did not experience progressive disease (PD) in the target lesion.
Death or development of distant disease was not regarded as an event.
For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Regional Progression-free Survival (RPFS) at 2-years
Time Frame: Up to 24 months
|
Percentage of patients that did not experience progressive disease (PD) in the target lesion.
Death or development of distant disease was not regarded as an event.
For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Distant Metastasis-free Survival (DMFS) at 2 Years
Time Frame: Up to 24 months
|
Percentage of patients that did not experience distant metastasis.
Death or development of distant disease was not regarded as an event.
For patients that underwent surgical resection, local progression was defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Distant Metastasis-free Survival (DMFS)
Time Frame: Up to 24 months
|
Percentage of patients without distant disease metastasis (progression of disease beyond local target lesion).
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Toxicities Associated With SBRT
Time Frame: Up to 24 months
|
Percentage of patients that experienced acute toxicity (defined as toxicity occurring within 3 months of completion of SBRT).
Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.
|
Up to 24 months
|
Late Toxicities Associated With SBRT
Time Frame: Up to 24 months
|
Percentage of patients that experienced late toxicity (defined as toxicity occurring after 3 months of completion of SBRT).
Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.
|
Up to 24 months
|
2-year Progression-free Survival (PFS)
Time Frame: Up to 24 months
|
Percentage of patients that did not experience disease progression at 2 years.
For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Time to Progression (TTP)
Time Frame: Up to 24 months
|
The time from enrollment to disease progression.
For patients that undergo surgical resection, local progression will be defined as disease recurrence detected on follow-up imaging (CT or FDG-PET/CT) that is located within the SBRT target volume.
|
Up to 24 months
|
Overall Survival (OS)
Time Frame: Up to 24 months
|
The length of time from enrollment to confirmed death from any cause.
|
Up to 24 months
|
Overall Survival (OS) at 1-year
Time Frame: Up to 12 months
|
Percentage of patients alive at 1-year (death from any cause).
|
Up to 12 months
|
Overall Survival (OS) at 2-years
Time Frame: Up to 12 months
|
Percentage of patients alive at 2-years (death from any cause).
|
Up to 12 months
|
Quality of Life (QoL) FACT-G
Time Frame: Up to 24 months (before treatment (baseline), shortly after neo-adjuvant treatment, shortly after surgery, shortly after SBRT, shortly after Adjuvant treatment)
|
The FACT-G is a 27 item questionnaire that assesses physical, social/family, emotional, and functional well-being, provided to patients and self-administered prior to SBRT, after completion of SBRT, and at each follow-up.
The survey takes 5 minutes to complete and employs as five-point scale from 0 (not at all) to 4 (very much).
Subscale scores added to obtain total score.
Scoring range is between 0-108 points.
Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate better QoL.
|
Up to 24 months (before treatment (baseline), shortly after neo-adjuvant treatment, shortly after surgery, shortly after SBRT, shortly after Adjuvant treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David A Clump, MD, UPMC Hillman Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCC 10-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Pancreas
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Kyowa Hakko Kirin Pharma, Inc.Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
-
National Cancer Institute, NaplesRecruitingAdenocarcinoma of the PancreasItaly, Spain
-
West Virginia UniversityRecruitingAdenocarcinoma of the PancreasUnited States
-
Baptist Health South FloridaAstraZenecaTerminatedAdenocarcinoma of the PancreasUnited States
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
National Taiwan University HospitalRecruitingDuctal Adenocarcinoma of the PancreasTaiwan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
Clinical Trials on Stereotactic Body Radiation Therapy (SBRT)
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Active, not recruitingPancreatic Cancer | Periampullary AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSarcoma | Metastatic Disease | Bony SitesUnited States
-
Virginia Commonwealth UniversityTerminatedProstate Adenocarcinoma | Stage I Prostate CancerUnited States
-
Centre Hospitalier Universitaire VaudoisActive, not recruitingProstate AdenocarcinomaSwitzerland
-
Centre Leon BerardTerminatedNon-small-cell Lung CarcinomaFrance
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawn
-
Washington University School of MedicineCompletedInoperable Stage I/II Non-small Cell Lung CancerUnited States
-
National Cancer Institute, NaplesRecruiting